# Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

> **NCT04896697** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Xilio Development, Inc.** · enrollment: 136 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** vilastobart (XTX101)
- **DRUG:** Atezolizumab
- **DRUG:** vilastobart (XTX101)

## Key facts

- **NCT ID:** NCT04896697
- **Lead sponsor:** Xilio Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-13
- **Primary completion:** 2026-06-12
- **Final completion:** 2026-06-12
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04896697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04896697, "Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04896697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*